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Detection of endotoxin-like interleukin-l-inducing activity during in
vitro dialysis. In order to study the integrity of dialysis membranes to
pyrogens, the dialysate side of a closed loop hemodialysis (HD) circuit
was challenged with E. coli microfiltrate containing 500 ng/ml endo-
toxin. Three solutions, a) tissue culture medium/saline, b) 5% human
serum albumin, and c) 10% fresh human plasma, were circulated in the
blood loop for five hours. Samples drawn from the blood side were
assayed for interleukin-l (IL-l)-inducing activity on human mononu-
clear cells (MNC) in vitro. No IL-i-inducing substances were detected
when saline or culture medium was circulated in the blood loop.
Circulating 5% human serum albumin revealed IL-i-inducing activity in
the samples drawn only after five hours of HD. However, the addition
of 10% fresh human plasma to the blood side resulted in the appearance
of an IL-i-inducing substance(s) after 15 minutes of HD. After 30
minutes, maximum IL-i-inducing activity was observed (control stim-
ulation index, 3.30 0.67 SEM vs. 7.59 1.50, P < 0.02). The
IL-i-inducing activity of the samples was completely inhibited by
polymyxin B, a cationic antibiotic which blocks the IL-i-inducing
activity of endotoxin. Additional experiments demonstrated that in
vitro MNC IL-i-production induced by the same E. coli microfiltrate is
enhanced in the presence of 10% plasma, These studies demonstrate
that: (a) in the presence of plasma, IL-I-inducing factors pass into the
blood compartment of a dialysis system challenged with bacterial
pyrogen; and (b) MNC production of IL-i is enhanced in the presence
of plasma. Since the Limulus test is influenced by plasma, in vitro
MNC-IL-1-production provides a more reliable and relevant assay to
determine dialysis membrane permeability for pyrogens.
Fever and symptomatic hypotension are well known phe-
nomena complicating routine hemodialysis (HD) therapy [1—8].
The fall in blood pressure during HD is frequently accompanied
by nausea, myalgia, headache, lassitude, and sleepiness. Some
of these symptoms also occur in patients suffering from injury,
infection, or inflammatory diseases and are known as acute
phase responses [9]. This first step in host response is mediated
by a family of polypeptides called interleukin-1 (IL-i) with
molecular weights of approximately 17000 daltons. Two distinct
IL-i gene products have been cloned [10, ii] and recombinant
human IL-i has been used to confirm its multiple biological
properties [12]. IL-i causes decreased plasma zinc and iron
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levels, increased hepatic synthesis of several acute phase
proteins, induces PGE2 production resulting in fever, and
stimulates PGI2 and platelet activating factor production which
are potent vasodilators [13, 14]. Many of these changes can
occur following hemodialysis, including symptomatic hypoten-
sion, and it has been proposed that these acute phase responses
may be due to IL-i produced during HD [15—171.
Although the dialysis membranes are considered to be imper-
meable for endotoxin (ET), fever during HD is associated with
bacterial contamination in the dialysate [4-8]. Humans are most
sensitive to the IL-i-inducing property of endotoxin in vivo (3
ng/kg of E. coli ET produce fever) and human monocytes
produce IL-i in vitro when incubated with ET concentrations
as low as 50 pg/mI [18]. We have recently demonstrated that
fresh human blood circulated through the blood side of a
closed-loop dialysis circuit is stimulated to produce IL-I when
ET is present on the dialysate side [19]. In contrast, the Limulus
amebocyte lysate (LAL) test has repeatedly failed to demon-
strate the passage of ET into the blood compartment under
various conditions despite highly contaminated dialysate [20,
21]. Since these studies [19—211 found positive results using
whole blood but not saline in the blood compartment, it seems
likely that proteins or other plasma components are necessary
to demonstrate the presence of endotoxin-like substances in the
fluid phase of the blood compartment. Although the LAL test is
able to detect ET in water or saline at concentrations as low as
5 to 10 pg/ml, assaying plasma samples with the Limulus test is
not useful due to false positive reactions caused by plasma
components, such as thrombin [22]. In addition, human mono-
cytes respond also to pyrogenic substances such as muramyl
peptides which are negative in the Limulus assay. Therefore, in
vitro human monocyte-IL-l production seems to be a more
reliable assay than the LAL test to determine dialysis mem-
brane permeability for pyrogens [23]. In addition, if dialysate is
contaminated, it consists of live bacteria and enzymatic degra-
dation products of ET rather than purified endotoxin as we and
others have used it previously [19—21].
Therefore, the present study was designed to clarify the
mechanism of IL-i-induction during in vitro dialysis with con-
taminated diaiysate. To test the effect of plasma components, in
vitro experiments were performed using three different solu-
tions to fill the blood side: (a) saline/cell culture medium; (b) 5%
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Fig. 1. Flow diagram of the in vitro dialysis circuit. Abbreviations are:
QB, "blood" flow, QD, "dialysate" flow; 1, hollow fiber dialyzer
(regenerated cellulose); 2, dialysate compartment (DC); 3, blood com-
partment (BC). Two different dialyzers were used: (A) 12 pm membrane
dialyzer, 0.8 m2 surface area. DC volume = 150 ml containing MEM
without or with E. coil filtrate, maintained at 37°C, Qn = 300 mI/mm.
BC volume = 150 ml containing MEM, 5% albumin or 10% plasma,
37°C, QB = 150 mI/mm. (B) 15 pm membrane dialyzer, 0.6 m2 surface
area. DC volume = 1200 ml containing saline without or with purified
endotoxin, maintained at 37°C, QD = 350 mI/mm. BC volume = 1100 ml
containing saline or 5% albumin, 37°C, Qa = 250 mI/mm.
human serum albumin in saline; and (c) 10% fresh human donor
plasma in cell culture medium. We also used two different,
regenerated cellulosic membranes to test the influence of mem-
brane thickness. In addition, to simulate in vivo conditions, we
used an E. coil culture microfiltrate (0.22 m) rather than
purified ET to challenge the dialysate side.
Methods
Preparation of E. coli culture microflitrate
E. coli were grown in brain-heart infusion broth in a shaking
water bath at 37°C for 24 hours. The cells were pelleted by
centrifugation and the supernatant was filtered through a 0.22
im filter. Sterility was confirmed on blood agar plates. The ET
concentration in the filtrate was approximately 50 g/ml mea-
sured by the Limulus amebocyte lysate (LAL) test (Pyrotell,
Associates Cape Cod, Woods Hole, Massachusetts, USA). The
filtrate was stored at 4°C until it was used to challenge the
dialysate side of the in vitro dialysis circuit.
The in vitro dialysis circuit
We used a closed loop dialysis system as shown in Figure 1.
The blood lines were standard hemodialysis line sets (G555,
Gambro Inc., Newport News, Virginia, USA). Two different,
regenerated cellulose capillary dialyzers were used: (a) 12 j.m
membrane dialyzer with a surface area of 0.8 m2 (Terumo Corp,
Tokyo, Japan); and (b) 15 pm membrane dialyzer with a surface
area of 0.6 m2 (Asahi Medical Co Ltd, Tokyo, Japan). Figures
in this paper employ "A" for conditions of the 12 pm and "B"
for the 15 m dialyzer. The system was assembled under
aseptic conditions and the blood and dialysate compartments
were each rinsed with 2 liters of sterile, pyrogen free saline. In
experiments using the 12 m dialyzer, the saline in the dialysate
side was replaced by sterile minimal essential medium, pH 7.4
(MEM, Microbiological Associates, Walkerville, Maryland,
USA) containing 10 mM HEPES, 2 mrs L-glutamine, 100 U/mI
penicillin and 100 jsg/ml streptomycin. LAL testing in these
media detected 10 to 100 pg!ml ET. The sterile medium in the
dialysate loop (volume = 150 ml) was circulated at a flow rate of
QD = 300 mllmin. After one hour of sterile HD, 1.5 ml of E. coli
culture microfiltrate was added to the dialysate loop (dilution
factor = 1: 100). Fifteen minutes later, the LAL test detected an
ET concentration of approximately 500 ng/ml in the dialysate.
The E. coli microfiltrate was circulated for an additional four
hours. The blood compartment (150 ml) contained one of the
following: (a) sterile MEM; (b) 5% human serum albumin
(Plasbumin-5, Cutter Biological, Berkely, California, USA); or
(c) 1: 10 dilution of fresh human plasma (heparinized with 10
U/ml) in MEM. As control, 10% plasma in MEM was circulated
for five hours against sterile MEM in the dialysate compart-
ment. In all experiments, the solution in the blood side was
circulated at a flow rate of QB = 150 mI/mm. Both loops were
kept at 37°C and circulated in a countercurrent manner for five
hours.
Samples from the dialysate loop were drawn at 15 minutes of
sterile HD and 75 minutes (15 minutes after the addition of the
E. coli microfiltrate). Samples from the blood loop were drawn
at 15, 30, 45, 60 minutes (sterile HD) and 75, 90, 105, 120, 300
minutes (E. coli microfiltrate) of circulation. Every sample (3
ml) was replaced by an equal volume of the corresponding
medium to maintain a constant circulating volume in both
compartments. All samples, including a relevant medium con-
trol (no contact to the dialysis circuit), were pre-incubated for
two hours at 37°C in the presence or absence of 5 g/ml
polymyxin B (PmB) (Pfizer Inc., New York City, New York,
USA), a inhibitor of ET-mediated monocyte stimulation. Fol-
lowing this, all samples were assayed for IL-I-inducing activity
on human mononuclear cells (MNC). In plasma experiments,
the same donor provided both plasma and cells.
Using a 15 tsm dialyzer (surface area 0.6 m2), similar exper-
iments were performed with saline as dialysate. The blood
compartment (volume: 1100 ml, QB = 250 ml/min) contained
either saline or 5% human serum albumin in saline. After a short
time of sterile HD (30 minutes in saline experiments, 5 minutes
in albumin experiments) the dialysate side (volume: 1200 ml,
QD = 350 ml/min) was challenged with 25 mg purified endo-
toxin (phenol extracted lipopolysaccharide from E. coil, Sigma,
St. Louis, Missouri, USA). One hour later, an ET concentra-
tion of 28 jsg/ml was measured in the dialysate by the LAL test
(Pyrogent, Buk-Mallickrodt, Dietzenbach, FRG). With saline
present in both compartments, in vitro HD was performed for
90 minutes and samples were drawn from the circuit after 30
minutes (blood side) and 90 minutes (both sides). Using 5%
albumin in the blood compartment, HD was performed for five
hours and samples were drawn after five minutes (blood side),
10 minutes and five hours (both sides). All samples were
assayed for IL-l-inducing activity on human MNC and for ET
in the LAL test.
IL-i measurement
Thymocyte assay. MNC were separated by Ficoll Hypaque
gradient centrifugation and resuspended in MEM containing 2%
heat-inactivated human AB serum, at a concentration of 5 X 106
cells/ml. Samples drawn from the in vitro dialysis system were
incubated in triplicate (0.1 ml/well) with equal volumes of MNC
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Fig. 2A. IL-I activity in samples drawn from the circuit containing MEM in both compartments (12 pin membrane). Solid bars depict IL-i activity
induced by BC samples without PmB; open bars depict BC samples with 5 sg/ml PmB. Stippled bars depict IL-I activity induced by DC samples
without PmB (open bar = 5 g/ml PmB). IL-I production from control MNC is indicated as MEM. The numbers under the horizontal axis indicate
the time (minutes of in vitro HD) when samples were removed and added to MNC. The amount of IL-I is expressed as mean of triplicate CPM
of 311-thymidine incorporation into thymocytes so. The results represent a single experiment. (B) IL-i activity by samples drawn from the circuit
containing saline in both compartments (dialyzer: 15 pm, 0.6 m2 surface area). Solid bars = BC samples, stippled bars = DC sample. Saline =
Control IL-i production from MNC. The numbers under the horizontal axis indicate the time (minutes of in vitro HD) when samples were removed
and added to MNC. The amount of IL-i is expressed as SI and represents the mean (± SEM) of three separate experiments.
suspension in 96 well, flat-bottom microtiter plates (A/S Nunc,
Roskilde, Denmark). During 24 hours of incubation, the cells
were kept at 37°C and exposed to an atmosphere containing 5%
CO2. After this period, the supernatants of the triplicate sam-
ples were removed, pooled in sterile 1.5 ml microcentrifuge
tubes and spun for five minutes at 4°C. The samples were
diluted I : 10 in RPMI 1640 containing 10 ma't HEPES (both from
Microbiological Associates, Walkersville, Maryland, USA), 2
mM L-glutamine, 100 U/mi penicillin, 100 pg/mi streptomycin
(all from Grand Island Biological Co. Grand Island, New York,
USA) and 5 x l0 M 2-mercaptoethanol (Eastman Kodak,
Rochester, New York, USA) and then assayed for IL-I activity
on murine thymocytes. ET-resistant C3H/HeJ mice (4 to 6
weeks old, Jackson Laboratories, Bar Harbor, Maine, USA)
were used as the source of thymocytes. The preparation of the
murine cells and the IL-l assay were performed as described
previously [241. The thymocytes were resuspended in RPMI
1640 containing 5% fetal calf serum (Sterile Systems, Logan,
Utah, USA) and used in a final concentration of 2.5 X 106
cells/mi. Just before use, I sg/ml of the mitogen phytohemag-
glutinin (PHA, Burroughs-Wellcome Co. Research Triangle
Park, North Carolina, USA) was added to the cells. Triplicate
samples of each MNC supernatant (0.1 mI/well) were added to
equal volumes of the thymocyte suspension in microtiter plates
(NUNC). Following incubation for 48 hours in a humidified 5%
CO2 atmosphere at 37°C, the samples were pulsed with 1
j.Ci/weil 3H-thymidine (6.7 CilmM, New England Nuclear,
Boston, Massachusetts, USA) and incubated for an additional
18 hours. Lysed cellular material was collected on glass fiber
filter paper with a cell harvester, added to organic scintillation
solvent (Ready-solv., Beckman Instruments, Fullerton, Califor-
nia, USA) and incorporated radioactivity was determined with
a liquid scintillation counter (Beckman Inst.). Since responsive-
ness to both PHA and an IL-i standard varies from one
thymocyte preparation to the next, all experimental and asso-
ciated control samples were tested simultaneously using the
same cell preparation, identical media composition and incuba-
tion conditions.
In single experiments, IL-I activity is expressed as mean of
triplicate counts per minute (CPM) of incorporated 3H-thym-
idine standard deviation (SD). To pooi the results of several
experiments, IL-i activity is expressed as a stimulation index
(SI) where the background activity of 3H-thymidine incorpora-
tion into murine thymocytes incubated with PHA alone was
assigned a value of 1. Data from the latter experiments are given
as the mean standard error of the mean (sEM). Significance
was assessed using the Student's t-test for paired values.
Radioimmunoassay for IL-I beta. We used an IL-i beta (1251)
RIA Kit (Cistron Biotechnology, Pine Brook, New Jersey,
USA). The sensitivity of the assay was 50 pg/ml IL-i beta
within a confidence limit of 95%.
Results
Effect of non-protein solution in the blood compartment
As depicted in Figure 2A, there was no IL-I-inducing activity
in the fluid phase of the blood side from the 12 sm dialyzer
within one hour of HD against sterile MEM or during four hours
of HD against E. coli filtrate (data represent a single experi-
ment). This finding is similar to results of experiments in which
there was no IL-l-inducing activity in the blood loop of the
dialyzer with dialysate containing approximately 28 pg/ml of
purified endotoxin (Fig. 2B, N = 3). In the latter study, all
samples drawn from the blood side were negative in the LAL
test (Pyrogent, sensitivity: 15 pg/mI).
Effect of albumin in the blood compartment
When the dialyzer was challenged with E. coli filtrate,
IL-l-inducing activity on MNC was detected in samples drawn
from the blood side containing 5% human serum albumin (Fig.
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Fig. 3A. IL-I activity by samples drawn from the circuit filled with 5% human serum albumin in saline (5% ALB) in BC and MEM in DC (12 .un
membrane). Solid bars depict stimulation of IL-i production by BC samples without PmB; open bars depict those samples with 5 sgIm1 PmB.
Stippled bars depict IL-i activity induced by DC samples without PmB (open bar = 5 jg/ml PmB). Five percent ALB depicts control IL-I
production from MNC. The numbers under the horizontal axis indicate the time (minutes of in vitro HD) when samples were removed and added
to MNC. IL-i activity is expressed as SI and represents the mean (± SD) of two separate experiments. (B) IL-i activity induced by samples drawn
from the circuit containing 5% human serum albumin in saline (5% ALB) in BC and saline in DC (dialyzer: 15 sm, 0.6 m2 surface area). Solid bars
= BC samples, stippled bars = DC samples. Five percent ALB = control IL-I production from MNC. The numbers under the horizontal axis
indicate the time (minutes of in vitro HD) when samples were removed and added to MNC. IL-i activity is expressed as mean of triplicate CPM
(so in all samples <10%), and represents a single experiment.
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Fig. 4. iL-I production from human MNC incubated
with samples taken from BC containing 10% fresh
human plasma in MEM (12 m membrane). Solid
bars depict stimulation of IL-i production by
samples without PmB; open bars depict those
samples with 5 g/ml PmB. Control IL-l production
from MNC is indicated as 10% plasma. The numbers
under the horizontal axis indicate the time (minutes
of in vitro HD) when samples were removed and
added to MNC. The amount of IL-I is expressed as
SI (±sEM) and represents the mean of 7 separate
experiments.
3A, N 2). Compared to the control (5% albumin), only the
sample drawn after 300 minutes of HD induced a significant
amount of IL-i. This IL-i-induction was blocked by PmB. In
another experiment using 5% albumin in the blood loop of a 15
pm dialyzer and purified ET (28 pgImI iii saline) in the dialysate,
we observed comparable results (Fig. 3B, a single experiment).
In contrast, the Limulus assay did not detect any positive
material in the 300 minute, blood loop sample.
Effect of 10% human plasma in the blood compartment
We next circulatedfresh human plasma in the blood compart-
ment. Figure 4 compares IL-I production by MNC incubated
with samples drawn from the blood compartment containing a
1: 10 dilution of fresh human plasma in MEM to IL-i production
by MNC incubated with the control solution of 10% plasma in
MEM (no contact to the dialysis circuit, N 7). All plasma
samples, including the control, induced MNC-IL- 1-production.
IL-I induction was blocked by PmB. Compared to the control
(SI = 3.30 0.67), no significant IL-i production was induced
by the samples drawn during one hour of sterile HD. In
contrast, after the dialysate side was challenged with E. coli
filtrate, the IL-i-inducing activity in the blood side increased to
5.77 1.37 (F < 0.05) within 15 minutes (75 minutes of HD) and
to 7.59 1.50 (P < 0.02) within 30 minutes (90 minutes of HD).
The samples drawn after 105, 120 and 300 minutes of HD
induced a similar amount of IL-i (P < 0.02). When 10% plasma
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Fig. 5. IL-i activity induced by samples drawn from both compart-
ments at two time points. BC samples including the control are the same
as shown in Figure 4 (10% plasma, 15 and 75 minutes). Symbols are: (U
without PmB; (L) with 5 jsg/ml PmB; (El) DC samples containing MEM
() E. coil filtrate to dialysate. The 15 minute DC sample is depicted
without (stippled bar) and with (open bar) PmB. The 75 minute DC
sample is depicted in log dilutions. MEM indicates control IL-i
production by MNC relevant for DC. The amount of IL-I is expressed
as SI (± saM) and represents the mean of 7 separate experiments.
in the blood compartment was circulated against sterile MEM
as the dialysate for five hours, no significant IL-I production
was induced by any sample (data not shown).
Figure 5 shows the IL-l production induced by blood side
samples and dialysate samples drawn at the same time (N = 7).
Compared to the corresponding control, no significant IL-I
production was induced by the samples drawn after 15 minutes
of HD. After 75 minutes of HD (15 minutes after challenging the
dialysate compartment with E. coli filtrate), significant IL-l-
inducing activity was detected in both blood side and dialysate
side samples.
To estimate the amount of IL- 1-inducing activity penetrating
the dialysis membrane, various concentrations of E. coli filtrate
diluted in MEM were compared to the activity in the 10%
plasma sample drawn at 75 minutes (right side of Fig. 5). The
amount of IL-i-inducing activity in the 10% plasma sample was
similar to the activity found in the 1: 10 dilution of the E. co/i
filtrate. To determine the influence of 10% plasma in the MNC
assay, log dilutions of E. co/i filtrate in either MEM or MEM
containing 10% fresh human plasma where tested on MNC.
After incubation, 10% plasma was added to the plasma-free
samples to reach comparable conditions in the IL-I assays.
Figure 6 shows the standard curve of the RIA in the presence of
10% plasma. As measured in the RIA, ET concentrations of 5 to
5000 ng/ml induced up to 10 times as much IL-l beta under the
conditions of plasma present in the MNC incubation (Fig. 7A).
In addition, 50 ng/ml ET in MEM containing 10% plasma and
5000 ng/ml ET in MEM alone induced a similar amount of IL-I
beta. Since the detection limit of the RIA was 50 pg/ml IL-I
beta, we assayed MNC supernatants also on murine thymoctes.
As shown in Figure 7B, IL-l activity is induced by ET concen-
trations as low as 50 pg/ml. Again, MNC IL- 1 production is
enhanced in the presence of plasma: 50 pg/mi ET in 10% plasma
induced as much IL-i as 500 pg/ml ET in MEM alone. There-
fore, the human monocyte response to the E. co/i culture filtrate
Fig. 6. Standard curve for the IL-I beta RIA. The standards were
prepared in MEM containing 10% plasma. The gamma CPM of each
standard were converted into x = % zero standard. On the horizontal
axis, x is expressed as logit x = LN (xJ(100—x)). The concentration of
IL-i beta standards is depicted on the y axis in nglml (logarithmic
scale). The detection limit within a 95% confidence is indicated by the
broken line.
seems to be enhanced one hundred-fold under the conditions of
fresh human plasma present in the incubation.
In addition, MNC were incubated in the presence or absence
of E. co/i filtrate (50 pg/ml LAL-reactive material) in: (a) MEM
alone; (b) MEM containing 10% fresh plasma; or (c) MEM
containing 10% fresh serum (same donor's blood was used as a
source for plasma and serum). Compared to the relevant
control, an increased IL-I production only occurred in the
presence of plasma plus ET.
Discussion
These results demonstrate that ET-like IL-i-inducing sub-
stances penetrate the seemingly intact, regenerated cellulose
membrane. However, in order to demonstrate this, plasma
needs to be present in the blood loop.
In this study, we investigated the influence of various in vitro
conditions on the ability of pyrogens present in the dialysate to
penetrate dialyzer membranes. To simulate contamination con-
ditions which occur in dialysate, we used a filtrate of an E. co/i
bacterial culture. The concentration of 500 ng/ml, as measured
by the LAL test, was used to challenge the dialyzer and this
amount of ET has been demonstrated in contaminated dialysate
used in hemodialysis units 1161. Using protein free solutions such
as saline or cell culture medium in the blood side, neither
IL-I-inducing activity nor LAL-positive materials could be
isolated from the fluid phase of the blood compartment. This
agrees with previous studies by other investigators [211 who
used the kinetic LAL method. Since the LAL test is known to
detect low concentrations of ET in water or saline (5 to 10
pg/mi), evidence is provided that under rinsing conditions as
performed prior to routine hemodialysis therapy less than 5
pg/mi ET is present in the fluid phase of the blood loop.
Circulating 5% human serum albumin in the blood loop
resulted in the detection of IL-l-inducing activity. After either
four or five hours of in vitro HD against ET-contaminated
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Fig. 7A. IL-I production from human MNC incubated with various concentrations of E. co/i filtrate (ET), by RIA measurement in duplicate.
Closed bars depict IL-l beta induced by ET diluted in MEM containing 10% fresh human plasma; stippled bars depict those dilutions in MEM
alone. Control indicates IL-i from MNC in medium alone (10% plasma or MEM) (below level of detection). Data represent one single experiment.
(B) IL-i production from human MNC incubated with various concentrations of E. coli filtrate (ET), as measured in the thymocyte assay. Closed
bars depict IL-i activity induced by ET diluted in MEM containing 10% plasma; stippled bars depict those dilutions in MEM alone. Control
indicates IL-l production induced by medium alone (10% plasma or MEM). The amount of IL-i is expressed as mean of triplicate CPM of
3H-thymidine incorporation into thymocytes.
dialysate, IL-i-inducing activity was isolated from the fluid
phase of the blood compartment. Consistent with other studies
[20], the LAL test did not detect any positive material in these
samples. In spite of negative LAL results we assume that the
IL-i-inducing activity is due to an ET-like substance because
the IL-i induction in these samples is blocked by PmB. The
most plausible explanation is that ET-like materials penetrate
the membrane in very low concentrations and become concen-
trated over time by binding to albumin. In addition, no differ-
ence was observed dependent on membrane thickness or ET
preparation (Fig. 3A and B). The albumin-bound ET is not
easily detected in the Limulus assay [25, 261 but recognized by
human MNC. These data support previous studies emphasizing
the difficulties in attempting to demonstrate ET in protein-
containing solutions using the LAL test [22].
In the experiments performed withfresh human plasma as the
blood replacement and E. coil filtrate in the dialysate, IL-I-
inducing activity was isolated from the blood side as early as 15
minutes after challenging the dialysate side. This rapid appear-
ance of IL-i-inducing substances in the fluid phase of the blood
loop may be explained by several factors. It is known that ET
purification with hot phenol results in the formation of large
molecular aggregates (106 to i07 daltons) which are excluded by
the dialysis membrane. However, after five hours of recircula-
tion at 37CC, desintegration of the large ET aggregates may take
place and smaller subunits of ET such as lipid A penetrate the
membrane. Several investigators have described ET subunits
less than 1000 daltons isolated from human body fluids [271.
These smaller fragments may be generated enzymatically in the
E. co/i filtrates. Size exclusion chromatography and gel electro-
phoresis have been used to detect small ET subunits with
biological activity [27]. The E. co/i filtrate used in the present
studies was subjected to high performance liquid chromatogra-
phy which revealed a peak of LAL reactive material elating
between 10 and 20,000 daltons.
Although the size of ET subunits in E. coli filtrates may play
Fig. 8. IL-I production from MNC incubated with 50 pg/mi E. coii
filtrate (ET) (on the right side). Culture medium contained MEM alone
(stippled bars), 10% fresh plasma in MEM (closed bars) or 10% fresh
serum (striped bars). IL-i induction by media alone (control) is depicted
on the left side. The amount of IL-i is expressed as mean of triplicate
CPM of 3H-thymidine incorporation into thymocytes so.
a role in these results, the effect of plasma in the blood side
seems to be of major importance. The data shown in Figure 5
suggest that approximately 10% of the IL-i-inducing activity in
the dialysate compartment is detectable in the blood compart-
ment. Since fresh plasma itself augments the IL-i-inducing
activity of E. co/i filtrate in the order of 100-fold (Fig. 7A and
B), the results depicted in Figure 5 represent penetration of less
than 0.1% (less than 500 pg/mI ET). it is unclear what is
responsible for this enhancing effect of fresh plasma. Since
fresh serum drawn from the same donor does not contain this
enhancing activity (Fig. 8), it seems unlikely, the effect is due to
complement activation. Since the IL-i-inducing activity recov-
ered in the plasma from the blood side was blocked by PmB,
this activity is probably related to endotoxin related substances
A
6
5
'p3
Additions to MNC: Control b000 500 50
ET, ng/ml
5 0.5
Additions to MNC: Control 5 0.5 0.05 0.005
ET, ag/mi
20
>( 15
10
MEM 10% 10%
Additions to MNC: Plasma Serum
MEM 10% 10%
Plasma Serum
+ + +
50 pg/mI ET
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or lipid A-containing fragments. The reduction of IL-i-inducing
activity in control (no contact to dialysis) samples suggest that
plasma likely enhances the small amount of ET present in the
tissue culture medium.
The reason plasma samples drawn from the blood side during
sterile HD also stimulate IL-i remains to be explained. Since
this IL-i induction is also blocked by PmB, it is possible that
small amounts of ET remaining in the blood lines or the dialyzer
membrane after sterilization are solubilized by the 10% plasma
solution but not by rinsing the system with saline. Although we
can not exclude accidental contamination of the circuit by
drawing the samples, this is unlikely because there is no
difference in the IL-i-inducing activity found in the control and
the samples drawn during sterile RD and, in addition, all MNC
cultures were bacteriologically sterile. Although there is evi-
dence that the regenerated cellulosic membrane itself stimulates
C5a which may result in IL-i production [28—311, the amount of
C5a which would be present during MNC incubation in the 5%
plasma solution (final concentration) is below that which was
necessary to stimulate IL-l production. However, we cannot
exclude complement activation during in vitro dialysis with
fresh plasma as playing a role in IL-i induction. Since plasma
enhances IL-i-induction by substances entering the blood com-
partment, evidence is provided that plasma components may
play a role in the onset of the acute phase response during
hemodialysis [16, 17]. Under in vivo conditions, plasma is
present in the blood loop at a concentration of about 60% rather
than 10%, and thus efforts should be directed to reducing the
pyrogen content of dialysate used in routine hemodialysis.
Reprint requests to Charles A. Dinarello, M.D., Division of Geo-
graphic Medicine and Infectious Diseases, Tufts University School of
Medicine and New England Medical Center, 750 Washington Street,
Boston, Massachusetts 02111, USA.
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